

AMENDMENTS TO THE CLAIMS

1-7 (withdrawn)

8 (original) A pharmaceutical composition comprising a protein useful for treating a lysosomal storage disorder other than Fabry disease that is selectively imported into macrophages when administered to a subject and a pharmaceutically acceptable carrier, wherein said protein is produced in an insect cell culture.

9 (currently amended) The composition of claim 8 wherein said lysosomal storage disorder is selected from the group consisting of Pompe Disease, GM1 gangliosidosis, Tay-Sachs disease, GM2 gangliosialidosis: AB Variant, Sandhoff Disease, Gaucher Disease, Krabbe Disease, Niemann-Pick Types A-D, Farber Disease, Wolman Disease, Cholesterol Ester Storage Disease, Hurler Syndrome, Scheie Syndrome, Hurler-Scheie, Hunter Syndrome, Sanfilippo A-D, Morquio A-B, Maroteaux-Lamy, Sly Syndrome, Metachromatic Leukodystrophy, Multiple Sulfatase Deficiency, Sialidosis, I-Cell Disease, Pseudo-Hurler Polydystrophy, Mucopolidosis IV, α -Mannosidosis, β -Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Galactosialidosis, Schindler Disease, Cystinosis, Salla Disease, Infantile Sialic Acid Storage Disorder, Batten Disease, Infantile Neuronal Ceroid Lipofuscinosis, and Prosaposin.

10 (currently amended) The composition of claim 8 wherein said protein is selected from the group consisting of acid α -1,4-glucosidase, acid α -1,6-glucosidase, β -galactosidase, β -hexosaminidase A, GM₂ Activator Protein, β -hexosaminidase A, β -

~~hexosaminidase B, glucocerebrosidase, β -glucosidase, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, acid lipase, α -L-iduronidase, iduronate sulfatase, α -N-acetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arylsulfatase B, β -glucuronidase, arylsulfatase A, arylsulfatase C, α -Neuraminidase, UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase, α -mannosidase, β -mannosidase, α -L-fucosidase, N-aspartyl- β -glucosaminidase, protective protein/cathepsin A (PPCA), α -N-acetyl-galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoyl-protein thioesterase, and Saposins A-D.~~

- 11 (original) The composition of claim 8 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricoplusia ni*.
- 12 (original) The composition of claim 11 wherein said cells are *Spodoptera frugiperda* Sf9 cells.
- 13 (original) The composition of claim 8 wherein said protein is produced in the cell culture using a baculovirus expression system.
- 14-20 (withdrawn)